Our Company
Our radiopharmaceuticals utilize novel molecules to precisely deliver targeted radiation to cancer cells for diagnosis and therapy.
-
Our Company
NORROY is a R&D-oriented biotech focused on the development and commercialization of radiopharmaceutical theranostics and automated synthesizer & functional modules for radiopharmaceutical production in both R&D and GMP settings.
Founded in July 2021, NORROY has developed more than 7 pipelines currently under clinical investigations for urological cancers, gastrointestinal & pancreatic cancers , lung cancers, breast & ovarian cancers, nasopharyngeal cancers, neurological cancers, and solid tumors. In addition to innovation of pipelines and automated modules, NORROY also continues to establish a solid global supply of multiple radioisotopes, build commercial GMP manufacturing facilities and global distribution network with international partners.
Up to date, NORROY has received 4 IND approvals from the U.S. Food and Drug Administration (FDA), and 4 IND approvals from the China National Medical Products Administration (NMPA), and works closely with the regulatory agencies to advance its late-stage pipelines through internationally registered clinical trial investigations.
Norroy 's sub business
Norroy Global Operations
Norroy has established operations not only in Wuxi, Nanjing, Maanshan in China, but also in the United States.
Our state of the art GMP grade and automated radiopharmaceutical production facility in Maanshan is one of the largest of its kind globally and expected to open in 2026 to deliver manufacturing solutions to meet clinical and commercial production requirements nationwide and globally.
Our state of the art GMP grade and automated radiopharmaceutical production facility in Maanshan is one of the largest of its kind globally and expected to open in 2026 to deliver manufacturing solutions to meet clinical and commercial production requirements nationwide and globally.
-
Research & Development Network
- 2x Radiochemistry Development Laboratories, China & United States
- 3x Preclinical Research Centers, China
- 1x Clinical Research Institute, China
- 1x Next Generation Intelligent, Automated Equipment Development Center, China
-
Clinical Network
- 15+ Research Hospitals with active, ongoing IIT&IND clinical trials, China
- 30+ Research Hospitals under negotiation to conduct 2 diagnostic Phase Ⅲ trials & 1 therapeutic Phase Ⅲ trial (pending NMPA approvals), China
- 3+ International Research Hospitals under negotiation (ex-China)
-
-
Norroy Anhui Co. Ltd., China
- 1 Class A GMP commercial production facility under construction (24,000m2)
-
Norroy Bioscience Co. Ltd., China
- 1 Class B GMP facility in operation (supplying clinical trial patient doses)
1 Class B GMP facility in renovation
Contact us - 1 Class B GMP facility in operation (supplying clinical trial patient doses)
-
Norroy Bioscience Nanjing Research Institute, China
- Leveraging regional advantages to build a top-tier radiopharmaceutical R&D platform and drive breakthroughs in theranostic innovation.
Contact us -
Norroy Programs by Disease Areas
Norroy's pipelines focus on unmet medical needs of the patients and healthcare professionals, in the disease areas including urological cancers, gastrointestinal & pancreatic cancers, lung cancers, breast & ovarian cancers, nasopharyngeal cancers, neurological cancers, solid tumors, and other diseases.
